Measurement of alveolar nitric oxide in IPF patients and in healthy controls
2014
Introduction: Exhaled Nitric Oxide (eNO) is a noninvasive and simple method of assessing airway inflammation. While its utility is well established in asthma, there are no studies in patients with Idiopathic Pulmonary Fibrosis (IPF). Aim: To measure eNO concentration in IPF patients, assess its correlation with lung function tests and its potential utility as a biomarker. Methods: Alveolar eNO was measured in 31 patient with IPF and 20 healthy volunteers. Mean eNO was compared between the two groups. Correlation with pulmonary function testswas investigated using Pearson correlation coefficient, regression analysis. Results: 27 IPF patients and 17 controls were able to complete all measurements. No patient or control was receiving any medication that could have an impact on eNO. Mean age was 64±10.09yrs. for patients and 55.45±8.9 for controls, 2 patients were non-smokers and 25 ex-smokers. eNO was 4.4963±3.88 ppb in patients versus 1.1118±1.46ppb in controls, respectively (p=0.0013). Mean FVC was 72.9±18.35 %pred. and mean lung DLco 40.33±11.43%pred. eNO was significantly correlated to FVC by both Pearson (p=0.01,r=0.46) and regression analysis (p=0.01, R 2 =0.22), although multiple regression analysis showed no statistical significance. However, we found no significant correlation with DLco by Pearson, regression analysis or multiple regression analysis. Conclusions: eNO is significantly higher among IPF patients and correlate positively with FVC,butnot with DLco. Bigger cohorts of patients are needed to draw definite conclusions.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI